FREE Shipping on all US Orders
CCCA is the most common scarring alopecia in Black women — and a 2026 UCLA study found it takes longer to diagnose than any other scarring hair loss. Here is why that matters.
CCCA affects 2.7-5.7% of Black women and is the most common scarring alopecia in this population. A February 2026 UCLA study confirmed CCCA has the longest time to diagnosis of any scarring alopecia. A May 2025 Mayo Clinic study confirmed CCCA patients are significantly less likely to improve following treatment compared to other scarring alopecias. These two findings together make one thing clear: early recognition is the most important variable in CCCA outcomes. Here is what to look for.
CCCA is progressive and permanently damages follicles. The earlier it is caught, the more follicles can be preserved. The 2026 UCLA study found CCCA takes longer to diagnose than any other scarring alopecia — meaning the population most affected is also the one waiting longest for an accurate diagnosis. That gap is what this article is for.
This series has covered androgenetic alopecia, alopecia areata, telogen effluvium, traction alopecia, and postpartum shedding. Today's article covers a condition that affects a significant population and receives far less attention than those better-known types: central centrifugal cicatricial alopecia — CCCA.
CCCA is a distinctive form of scarring alopecia characterized by patches of permanent hair loss that manifest on the vertex or crown of the scalp, progressively spreading outward in a centrifugal pattern. It is predominantly observed in women of African descent, displaying a familial predisposition.
CCCA affects 2.7-5.7% of Black women and is the most common form of scarring alopecia in this population. It causes progressive, permanent follicle destruction. And a February 2026 study from UCLA published in the Journal of Drugs in Dermatology found something that makes both of those facts more urgent: CCCA is associated with longer time to diagnosis than any other scarring alopecia — a documented health disparity that directly affects outcomes.
The reason early diagnosis matters so much is straightforward: scarred follicles cannot be restored. Progression can be slowed with treatment. Destroyed follicles cannot be recovered. The gap between when CCCA begins and when it is correctly identified and treated is the gap in which permanent follicle loss accumulates.
What CCCA Is
The mechanism — and why it is different from every other hair loss type in this series.
CCCA is a scarring alopecia — meaning the inflammatory process destroys the hair follicle and replaces it with fibrous scar tissue. This places it in a fundamentally different category from AGA (follicle miniaturisation), alopecia areata (autoimmune attack on an intact follicle), telogen effluvium (temporary disruption of cycling), and traction alopecia (mechanical stress). In all of those conditions, the follicle is damaged but potentially recoverable. In CCCA, once the follicle is replaced by scar tissue, it is gone.
Histology of CCCA reveals perifollicular lymphocytic inflammation of the lower infundibulum, premature desquamation of the inner root sheath, and fibrous connective tissue replacing the follicular structure. The premature desquamation of the inner root sheath is considered a hallmark feature — it is the earliest detectable change and represents the starting point of the inflammatory cascade that eventually destroys the follicle.
A genetic susceptibility has been identified in approximately one-third of women studied: loss-of-function variants affecting the enzyme PADI3, which modifies proteins involved in hair growth. This genetic factor — inherited in an autosomal dominant pattern in some families — means CCCA runs in families, and a family history of the condition is a meaningful risk flag.
What to Watch For
The earliest signs — and why they are regularly missed.
CCCA typically begins at the crown or vertex of the scalp and progresses outward in a circular pattern — which is where the "centrifugal" in its name comes from. The earliest signs are often subtle and easily attributed to other causes:
Symptoms including scalp pain, tenderness, itching, or a burning sensation at the crown are often the first subjective signs of active CCCA inflammation. These symptoms precede visible hair loss in many cases — which means they represent the window where intervention can preserve follicles that have not yet been destroyed. These symptoms are frequently attributed to product sensitivity, tight styling, or seborrhoeic dermatitis rather than triggering evaluation for scarring alopecia.
As CCCA progresses, the affected area develops a smooth, shiny appearance — the visual sign of scar tissue replacing the normal scalp surface. The hair follicle openings (ostia) disappear. This is the sign that indicates active fibrosis has occurred and follicles in that area have been permanently destroyed. Trichoscopy — a dermoscope at 10x magnification — reveals the absence of follicular openings and the characteristic features of scarring alopecia. This is one reason trichoscopy by a dermatologist or trichologist familiar with CCCA is essential for correct diagnosis.
The centrifugal spread from crown outward distinguishes CCCA from AGA (which also affects the crown but presents with miniaturisation rather than scarring) and from traction alopecia (which affects the hairline and edges). The combination of crown-centred onset, symmetric outward progression, and the scalp changes described above — in a Black woman with a family history — is a clinical picture that warrants immediate dermatological evaluation, not watchful waiting.
Treatment — Honest About the Limits
What exists, what helps, and what doesn't yet.
Despite its high prevalence, CCCA remains understudied. Patients with CCCA were significantly less likely to report improvement following treatment compared to controls with non-CCCA scarring alopecia. The May 2025 Mayo Clinic case-control study of 54 biopsy-confirmed CCCA patients confirmed this — the treatment response is more limited than for other scarring alopecias.
Current treatment modalities — topical and systemic corticosteroids, oral tetracyclines, hydroxychloroquine — aim to reduce inflammation and slow progression rather than reverse damage. Treatment options for CCCA remain limited, with current modalities encompassing anti-inflammatory approaches. Topical metformin has been explored in recalcitrant cases in a 2025 JAAD case series, and apremilast (a PDE4 inhibitor) was studied in a pilot trial at Mount Sinai — these represent emerging research directions, not established standard of care.
The practical implication: treatment reduces inflammation and can slow or halt progression. It cannot restore scarred follicles. Early treatment — when active inflammation is present but before extensive fibrosis — is the most important determinant of how much follicle density is preserved over time.
The association between CCCA and traumatic styling practices — chemical relaxers, hot combs, tight tension styles — has been discussed in the literature for decades. A Mayo Clinic cohort found that all CCCA patients had a history of traumatic styling practices including high-tension styles, chemical relaxers, and heated styling tools.
The honest scientific position: current postulates include genetic inheritance, with traction-inducing hairstyling practices and hair chemicals as aggravating factors — not sole causes. The PADI3 genetic finding suggests a genetic predisposition that styling practices may aggravate or accelerate. This is not a blame framing — it is a recognition that both factors exist and that reducing the aggravating factors while addressing the underlying inflammation is the current clinical approach. Some women with the same styling practices never develop CCCA; some develop it without extensive chemical or traction history.
What to do if you recognise these signs.
If you are a Black woman experiencing scalp tenderness or itching at the crown, noticing the early signs of crown hair thinning, or have a family member with diagnosed CCCA — seek evaluation from a dermatologist specifically experienced with scarring alopecias, ideally one who performs trichoscopy. A general practitioner or a dermatologist without specific interest in hair loss may miss the early signs of CCCA or attribute them to other causes, contributing to the diagnostic delay the 2026 UCLA study documented.
Ask specifically for trichoscopy and, if warranted, a scalp biopsy. These are the tools that distinguish CCCA from AGA, seborrhoeic dermatitis, and traction alopecia at a stage where intervention still matters. The earlier the correct diagnosis, the more of your follicles can be preserved.
And the one that takes the longest to diagnose. Knowing the signs closes that gap.
Anti-inflammatory scalp care — relevant to the CCCA environment.
The Laritelle ritual does not treat CCCA — that requires medical intervention. Anti-inflammatory botanical care supports the scalp environment alongside medical treatment, and a pH-balanced microbiome-supportive routine reduces the inflammatory substrate where CCCA operates.
→ Explore Hair Treatments → Explore ShampoosScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.